Evaluation of complications of Carmustin Wafer implantation in recurrent GBM

G. Satilmis, S.M.A. Zella, M. Wallocha, J. Schroeteler, H.J. Steiger & M.C. Sabel
Objective: Carmustine (1,3-bis [2-chloroethyl]-1-nitrosourea, or BCNU, GliadelĀ©) wafers are approved for treatment of recurrent glioblastoma and newly diagnosed malignant glioma (MG). Since the approval studies were performed prior to the introduction of combined radiochemotherapy (Stupp[for full text, please go to the a.m. URL]